We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bugs or drugs, tortoises or hares?
- Authors
Jacobs, Tom
- Abstract
The article presents information on latest developments in the field of biotechnology. In biotech, most investors have favored drug-makers over companies using advances to create better protein catalysts enzymes and microorganisms. After all, drugs are high-profile, high-margin products, offering patent-protected profits in markets that are theoretically unlimited. Novozymes AS shows steadily rising revenues from a range of enzyme and microorganism product programs. Genomics boom allowed at least three other companies to go public and call attention to their own directed molecular evolution techniques.
- Subjects
BIOTECHNOLOGY; CHEMICAL inhibitors; MOLECULAR genetics; GENETIC research; MOLECULAR biology; MEDICAL sciences
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 3, p293
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0305-293